Acta Med. 2004, 47: 181-185

https://doi.org/10.14712/18059694.2018.88

The Multidrug Resistance and Apoptosis Evaluation in Acute Myeloid Leukemia Cells After the In Vitro Doxorubicin Treatment

Karolína Jankovičováa, Jan Krejseka, Otakar Kopeckýa, Jaroslava Voglováb, Zuzana Škrabkovác, Jakub Novosada

aCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Department of Clinical Immunology and Allergology, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Department of Clinical Hematology, Hradec Králové, Czech Republic
cCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Department of Medical Biophysics, Hradec Králové, Czech Republic

Received April 1, 2004
Accepted May 1, 2004

References

1. Arceci RJ. Can multidrug resistance mechanisms be modified? Br J Haematol 2000; 110:285–91. <https://doi.org/10.1046/j.1365-2141.2000.02063.x>
2. Burnett AK, Kell J, and Rowntree C. Acute myeloid leukemia: therapeutic indications. Curr Opin Hematol 2000; 7:333–8. <https://doi.org/10.1097/00062752-200011000-00002>
3. Del Poeta G, Venditti A, Stasi R. et al. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leuk Res 1999; 23:451–65. <https://doi.org/10.1016/S0145-2126(98)00191-X>
4. Efferth T, Fabry U, Osieka R. Apoptosis and resistance to daunorubicin in human leukemic cells. Lekemia 1997; 11:1180–6. <https://doi.org/10.1038/sj.leu.2400669>
5. Elkon KB. Caspases: Multifunctional proteases. J Exp Med 1999; 190:1725–7. <https://doi.org/10.1084/jem.190.12.1725> <PubMed>
6. Filipits M, Stranzl T, Pohl G et al. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia 2000; 14:68–76. <https://doi.org/10.1038/sj.leu.2401634>
7. Karp JE and Mookerjee BP. Overcoming drug resistance: targeting more than on site. Leuk Res 2002; 26:107–9. <https://doi.org/10.1016/S0145-2126(01)00123-0>
8. Kasimir-Bauer S, Ottinger H, Meusers P et al. In acute myloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance- related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 1998; 26:1111–7.
9. Legrand O, Simonin G, Zittoun R, Marie JP. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia 1998; 12:1367–4. <https://doi.org/10.1038/sj.leu.2401117>
10. Legrand O, Zittoun R, Marie JP. Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 1999; 13:578–84. <https://doi.org/10.1038/sj.leu.2401361>
11. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (mdr1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997; 89:3323–9.
12. Michieli M, Damiani D, Ermacora A et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol 1999; 104:328–35. <https://doi.org/10.1046/j.1365-2141.1999.01172.x>
13. Ramachandran Ch and Melnick SJ. Multidrug resistance in human tumors – molecular diagnosis and clinical significance. Mol Diagnosis 1999; 4:81–94. <https://doi.org/10.1016/S1084-8592(99)80033-2>
14. Reed JC. Bcl-2 family protein and mechanisms of chemoresistance in lymphomas and leukemias. Adv Leuk Lymph 1995; 5:3–11.
15. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest 1999; 104:1655–61. <https://doi.org/10.1172/JCI9053> <PubMed>
16. Suarez L, Vidriales B, Garcia-Larana J et al. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia. Haematologica 2001; 86:1287–95.
17. Tolomeo M, Grimaudo S, Milano S et al. Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines. Br J Pharmacol 2002; 135:1588. <https://doi.org/10.1038/sj.bjp.0704601>
18. Tsuji K, Motoji T, Sugawara I et al. Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. Br J Haematol 2000; 110:370–8. <https://doi.org/10.1046/j.1365-2141.2000.02181.x>
19. Vermes I, Haanen C, Richel DJ, Schaafsma MR, Kalsbeek-Batenburg E. and Reutelingsperger CPM. Apoptosis and secondary necrosis of lymphocytes in culture. Acta Haematol 1997; 98:8–13. <https://doi.org/10.1159/000203546>
20. Willman Ch. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Sem Oncol 1997; 34(suppl 5):25–33.
21. Wuchter C, Karawajew L, Ruppert V et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999; 13:1943–53. <https://doi.org/10.1038/sj.leu.2401605>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive